Intradialytic Hypoglycemia Causes and Mechanisms

Primary Pathophysiologic Mechanisms

Decreased gluconeogenesis by the kidneys is a fundamental cause of intradialytic hypoglycemia, as the kidneys normally contribute 20-40% of overall glucose production, which can increase two- to threefold during fasting or hypoglycemia, according to the Endocrine Society 1, 2
Impaired insulin clearance occurs because kidneys are responsible for a larger proportion of exogenous insulin metabolism, leading to prolonged insulin action, as stated by the Endocrine Society and Diabetologia 1, 3
Reduced insulin degradation by the kidney, liver, and muscle due to uremia further extends insulin half-life, as reported by the Endocrine Society 1, 4

Increased erythrocyte glucose uptake during hemodialysis creates an additional glucose sink that depletes plasma glucose, according to the Endocrine Society 1, 4
Dialysate glucose concentration is the main determinant of plasma glucose levels after hemodialysis, with glucose-free or low-glucose dialysate significantly increasing hypoglycemia risk, as stated by the Endocrine Society 1

Impaired counterregulatory hormone responses result in blunted hormonal responses to falling glucose levels, according to the Endocrine Society and Praxis Medical Insights 1, 2
Nutritional deprivation is both a cause and consequence of hypoglycemia in dialysis patients, with poor nutritional status being particularly common, as reported by the Endocrine Society and Praxis Medical Insights 1, 2
Medication effects, including insulin therapy and oral hypoglycemic agents, are exacerbated by the above mechanisms, as stated by the Endocrine Society and the American Journal of Kidney Diseases 1, 5

Elderly patients particularly fail to perceive neuroglycopenic and autonomic hypoglycemic symptoms despite comparable reaction time prolongation, according to Diabetes Care 6
Diabetic patients on insulin or sulfonylureas face compounded risk from both medication effects and dialysis-related mechanisms, as reported by the American Journal of Kidney Diseases 5, 7
Patients with acute kidney injury have additional risk due to decreased insulin clearance, as stated by Diabetes Care 8
The American Journal of Kidney Diseases recommends adjusting insulin doses when transitioning patients from earlier CKD stages to dialysis, as insulin requirements typically decrease by 40-50% 1, 4, 5, 7
The Endocrine Society suggests providing carbohydrate-rich snacks during dialysis for patients with pre-dialysis glucose ≤100 mg/dL, as reported by Praxis Medical Insights 2

Impaired renal insulin clearance, loss of kidney gluconeogenesis (eliminating roughly 20‑40 % of glucose production), defective insulin degradation from uremia, increased erythrocyte glucose uptake during hemodialysis, and blunted counter‑regulatory hormone responses collectively predispose patients with ESRD to hypoglycemia – Endocrine Reviews. 9
Renal gluconeogenic capacity is essentially absent in ESRD, removing a key endogenous defense against falling plasma glucose – Endocrine Reviews. 9
Uremic toxins disrupt insulin catabolism in the kidney, liver, and skeletal muscle, prolonging insulin half‑life in circulation – Endocrine Reviews. 9
During hemodialysis, erythrocytes take up glucose at an accelerated rate, creating an additional glucose sink that can markedly lower plasma glucose – Endocrine Reviews. 9
The cortisol and growth‑hormone responses to hypoglycemia are attenuated in ESRD, further compromising endogenous glucose‑raising mechanisms – Endocrine Reviews. 9

Patients with ESRD experience pronounced glycemic variability, with frequent episodes of both hypoglycemia and hyperglycemia – Endocrine Reviews. 9

Observational data suggest that targeting an HbA1c of 7 %–8 % (rather than < 7 %) is associated with lower mortality and reduced hypoglycemia risk in ESRD – Endocrine Reviews (observational evidence). 9
HbA1c alone is unreliable in ESRD because anemia, erythropoietin therapy, shortened erythrocyte lifespan, and transfusions can falsely lower values; alternative glucose monitoring strategies are required – Endocrine Reviews. 9 (Note: this point is inferred from the broader discussion of HbA1c limitations in the cited source.)